Ostrowieckie Centrum Medyczne Anna Olech Cudzik Krzysztof Cudzik s.c. — Clinical Trial Site

41 Registered trials

9 Currently recruiting

Organisation

Ostrowieckie Centrum Medyczne Anna Olech Cudzik Krzysztof Cudzik s.c.

Location

Ostrowiec Swietokrzyski, Poland

Identifier

ORG-100039873

Address

Ul. Ilzecka 31a, 27-400, Poland

Departments

-
8502:Cardiology
n/a
NA
Ostrowieckie Centrum Medyczne
Ostrowieckie Centrum Medyczne Anna Olech Cudzik Krzysztof Cudzik s.c.
Ostrowieckie Centrum Medyczne s. c.
Ostrowieckie Centrum Medyczne s.c. (#1)
Ostrowieckie Centrum Medyczne spolka cywilna Anna Olech-Cudzik, Krzysztof Cudzik
Ostrowieckie Centrum Medyczne spółka cywilna Anna Olech-Cudzik, Krzysztof Cudzik
Pneumology
private site

Clinical trials at this site (41)

Search interface

An Open-Label Extension to Study the Long-Term Effect of Dexpramipexole in Participants with Severe Eosinophilic Asthma (EXHALE-5) Under evaluation

2024-510810-33-00 Severe eosinophilic asthma 5 2024-10-14
Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults with Non-cystic Fibrosis Bronchiectasis (NCFB) Pending

2024-518821-13-00 Non-cystic Fibrosis Bronchiectasis 4
BETRI-Prospective: Asthma control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 µg]) vs Single Inhaler ICS/LABA (200/… Pending

2025-524289-56-00 Asthma 6
Long-term safety and efficacy evaluation of lunsekimig (SAR443765) in adult participants with moderate-to-severe asthma. Recruiting

2025-522896-27-00 Asthma 4 2026-05-11
A study to investigate airway inflammation with dupilumab subcutaneously in participants aged ≥40 to ≤85 years with chronic obstructive pulm… Recruiting

2025-521268-37-00 Respiratory tract diseases 6 2025-11-25
Therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in subjects with mild to moderate asthma (TRECONY) Recruiting

2025-521456-35-00 Mild to moderate asthma 4 2026-04-13
Phase 2b study of S-337395 in symptomatic nonhospitalized adults with respiratory syncytial virus (RSV) who are at high risk of progression… Recruiting

2025-523156-31-00 Respiratory Syncytial Virus 4 2026-03-17
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
Study of lunsekimig (SAR443765) compared with placebo in adults with high-risk asthma Recruiting

2024-513959-33-00 Asthma 4 2025-05-13
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-t… Recruiting

2024-512496-12-00 Moderate to Severe Plaque Psoriasis 5 2025-04-01
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C… Recruiting

2023-507407-59-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-07-04
A Study Evaluating the Efficacy and Safety of Povorcitinib (INCB054707) in Adults With Inadequately Controlled Moderate to Severe Asthma Recruiting

2022-502570-16-01 Treatment of patients with inadequately controlled mode 4 2024-06-27
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants with Severe Asthma Ended

2024-519469-23-00 Severe Asthma 4 2025-10-20
A Study to Assess the Effectiveness and Safety of Taplucainium Inhalation Powder (NOC-110) in Adults with Refractory or Unexplained Chronic … Ended

2024-515026-86-00 Refractory or Unexplained Chronic Cough 4 2024-12-18
A Phase 2, Double-blind, Placebo-controlled, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma Ended

2023-508039-29-00 Moderate-to-severe Asthma 4 2024-09-16
A Randomized, Double Blind, Active-Controlled Study on Efficacy and Safety of TEV-56248 in Patients with Asthma Ended

2023-505435-12-00 Asthma 5 2024-06-04
A study to investigate long-term safety and tolerability of itepekimab in participants with COPD Ended

2023-508085-15-00 Chronic Obstructive Pulmonary Disease 5 2024-05-15
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
A Phase 3, 52-Week, Randomized, Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory or Une… Ended

2024-513460-26-00 Refractory Chronic Cough, Including Unexplained Chronic 5 2023-03-29
A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended

2023-507795-51-00 atherosclerotic heart and blood vessel disease (the nar 5 2022-05-17
Clinical trial of statins CAncer preventive and Pleiotropic TherApy IN smokers with chronic obstructive pulmonary disease (COPD) Ended

2024-516714-37-00 Chronic obstructive pulmonary disease (COPD) 5 2022-01-19
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended

2024-510735-21-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2021-11-26
A study to assess and compare safety and tolerability of 3 months treatment with salbutamol administered via MDI containing propellant HFA-1… Ended

2023-509001-76-00 Asthma 5 2024-07-01
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants with Severe Asthma (VALIANT) Ended

2023-507410-27-00 Severe Asthma 4 2024-06-19